13.69MMarket Cap-35P/E (TTM)
11.000High10.487Low10.58KVolume10.850Open10.850Pre Close113.92KTurnover0.88%Turnover Ratio0.11P/E (Static)1.27MShares82.00052wk High6.62P/B12.90MFloat Cap6.42552wk Low--Dividend TTM1.20MShs Float22220.000Historical High--Div YieldTTM4.73%Amplitude6.425Historical Low10.770Avg Price1Lot Size
Redhill Biopharma Stock Forum
RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines
Benzinga· 2 mins ago
RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma
RedHill Biopharma (Nasdaq: RDHL) has announced that the FDA has granted orphan-drug designation to opaganib for the treatment of neuroblastoma, a rare childhood cancer.
This designation provides seven years of marketing exclusivity if approved and may offer additional benefits such as accelerated development and review times, potential grant funding, and tax credits...
Benzinga· 1 min ago
The commercial launch of Talicia in the UAE triggers RedHill's eligibility for additional potential milestone payments, minimum sales payments and tiered royalties up to mid-teens on net sales. Talicia is the first approved low-dose rifabutin-cont...
RedHill Biopharma Ltd., a specialty biopharmaceutical company, recently announced promising results from studies on the investigational drug opaganib. These studies, carried out in collaboration with Apogee Biotechnology Corporation, have highlighted opaganib's potential in managing obesity and Type 2 diabetes. $Redhill Biopharma (RDHL.US)$
https://stockregion.app/p/biopharmaceutical-company-announces-21e
No comment yet